Cimeta

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cimeta

What is Cimeta? Defining Identity and Purpose

Property Description
Active ingredient Cimetidine
Form Oral tablet, Oral solution, Injectable solution
Pharmacological class Histamine H2 Receptor Antagonist (H2 Blocker)
General purpose Reduction of gastric acid secretion
Origin Synthetic
Status Both Prescription (Rx) and Over-The-Counter (OTC) forms are common

Identity, Composition, and Origin

Cimeta is a proprietary name for the medicine containing the active substance Cimetidine (INN), which is a compound synthesized in the laboratory. Cimetidine is classified as a single-ingredient pharmaceutical and is widely available in forms suitable for the oral route, such as tablets and a liquid solution, as well as a sterile solution for injection. The versatility in formulation allows its use in various settings from hospital care to retail OTC options.

The active component, Cimetidine, is a N-substituted guanidine derivative, confirming its synthetic origin. This substance was a pioneering development in its class, established for use in acid suppression.


Pharmacological Class and General Purpose

Cimetidine belongs to the Histamine H2 receptor antagonist class, also known as an H2 blocker, which signifies its role in regulating the digestive system's acid output. The fundamental purpose of this drug is the significant reduction of gastric acid secretion in the stomach.

The drug achieves this by competitively blocking specific H2 receptor sites on the acid-producing cells of the stomach lining. H2 blockers lower the concentration of acid in the stomach lumen. This mechanism means the medicine acts directly to suppress the body’s signaling for acid release. In practical terms, this helps ease discomfort by reducing the core cause of the burning sensation associated with heartburn and acid indigestion.

Regulatory References

  1. FDA DailyMed Label for Cimetidine
  2. NIH MedlinePlus Cimetidine Information

What side effects are possible with Cimeta?

Possible Side Effects and Safety Information

The safety profile for Cimeta includes documented adverse reactions and specific usage limitations as defined by regulatory bodies.


Frequency-Classified Adverse Reactions

Side effects are categorized by the approximate frequency with which they occur, according to clinical data:

  • Common (1% to 10%): Includes headache, dizziness, diarrhea, and tiredness. Skin rashes and muscle pain (myalgia) have also been documented.
  • Uncommon (0.1% to 1%): Effects reported include confusion, hallucinations, depression, tachycardia, and increases in plasma creatinine. Reversible sexual effects such as gynecomastia (breast enlargement in men) and impotence are also noted.
  • Rare to Very Rare (<0.1%): This classification covers serious but infrequent events, such as blood disorders (agranulocytosis, thrombocytopenia, aplastic anaemia), severe allergic reactions (anaphylaxis), liver inflammation (hepatitis), and cardiac conduction issues (heart block, sinus bradycardia).

System-Organ Class Considerations

Adverse effects are grouped by the body system they affect, highlighting key risk areas:

  • Nervous System: Reversible confusional states are specifically noted, particularly in elderly patients (50 years or more) and those who are severely ill or have underlying kidney or liver impairment.
  • Endocrine and Reproductive System: Hormonal effects such as gynecomastia and sexual dysfunction are reported, predominantly with high doses or long-term use.

Safety-Related Restrictions

Formal safety documentation specifies restrictions and necessary precautions for use:

  • Drug-Drug Interactions: Cimeta can increase the blood levels of other medications by affecting liver enzymes (Cytochrome P450). This interaction is clinically significant for drugs like Warfarin, Phenytoin, and Theophylline, requiring careful monitoring.
  • Renal Impairment: Reduced dosage is required in patients with impaired kidney function (creatinine clearance below 50, mL/ minute) to minimize the risk of drug accumulation and potential toxicity, particularly central nervous system effects.

Overdose and Emergency Response

The official regulatory profile for Cimeta (Cimetidine) overdose is defined by the documented acute toxicity profile and mandated emergency response.

Overdose Manifestations and Acute Toxicity

Official regulatory information indicates that acute overdosage of Cimeta is generally associated with a low risk of severe symptoms. Reports documented by health authorities cite ingestion of high doses, up to 20 grams, as having resulted in no significant ill effects. Specific physiological systems or severe clinical signs resulting from isolated acute overdose are not explicitly detailed in the dedicated official prescribing information. No specific antidote is documented or listed in the regulatory guidance. This approach dictates that management is supportive in nature.


Emergency Actions and Clinical Management

Regardless of the documented acute toxicity profile, government labeling mandates that immediate medical help must be obtained right away following a suspected overdose. The individual must seek professional assistance and contact a Poison Control Center without delay. The regulatory guidance specifies that management should consist of symptomatic and supportive therapy. As officially documented procedural steps, clinical management may include methods such as the induction of vomiting or gastric lavage for gastrointestinal clearance. No population-specific differences in overdose severity are noted in the official regulatory documentation.

Therapeutic Uses of Cimeta

Main Uses of Cimeta

Cimeta is a medication primarily indicated for the treatment of conditions related to excess stomach acid production. It belongs to a class of drugs known as H2-receptor antagonists. Its primary applications include:

  • Gastric and Duodenal Ulcers: It is used to promote the healing of ulcers in the stomach and the upper part of the small intestine. It also helps prevent these ulcers from recurring once they have healed.
  • Gastroesophageal Reflux Disease (GERD): Cimeta is used to manage symptoms such as heartburn and acid regurgitation caused by the backflow of stomach acid into the esophagus.
  • Erosive Esophagitis: The medication aids in the healing of inflammation and tissue damage in the esophagus resulting from chronic acid exposure.
  • Hypersecretory Conditions: It is prescribed for rare medical conditions where the stomach produces extreme amounts of acid, such as Zollinger-Ellison syndrome.

Therapeutic Benefits

The primary benefit of Cimeta is the reduction of acid secretion in the digestive tract. By blocking the action of histamine on the acid-producing cells of the stomach lining, the medication provides several clinical advantages:

Symptom Relief

By lowering the volume and concentration of stomach acid, Cimeta helps alleviate the burning sensation and discomfort associated with indigestion and acid reflux. This can lead to an improved quality of life for individuals experiencing chronic digestive distress.

Tissue Healing

In cases where the lining of the stomach or esophagus has been damaged or ulcerated, a less acidic environment is essential for the body's natural repair processes. Cimeta facilitates this by maintaining a higher pH level in the gastric juices, allowing lesions to close and heal over time.

Prophylactic Support

For patients prone to recurrent ulcers or those taking specific medications that may irritate the stomach lining, Cimeta can be used as a preventive measure to reduce the risk of new ulcer formation.

Regulatory References

  1. NIH MedlinePlus overview of Cimetidine

Eligibility and Restrictions for Use

Cimeta's eligibility is strictly defined by regulatory authorities based on patient profile and underlying health status, determining who can use the medicine and who must not.

Populations Who Must Not Use Cimeta

Cimeta is contraindicated for any individual with a known hypersensitivity to mathbfcimetidine itself or to any other mathbfH2mathbf-receptor antagonist.

Age and Organ Function Restrictions

The medicine is typically approved for use in adults and adolescents (ge 12 years). Prescription use is documented for children ge 1 year old, but use in mathbfinfants (mathbf< 1 year) is considered mathbfnot fully established by regulators. mathbfGeriatric patients and mathbfseverely ill patients must use Cimeta with caution due to an increased risk of central nervous system effects.

Eligibility is conditional on organ health. Patients with impaired renal function are only eligible if a mathbfdosage reduction is implemented. Use is restricted to with caution in cases of mathbfhepatic insufficiency. For gastric ulceration in older patients, mathbfmalignancy must be excluded before initiating treatment.

Pregnancy and Lactation Status

The medicine mathbfshould be avoided during mathbfpregnancy and mathbflactation unless its use is mathbfconsidered essential by a health professional, as the drug is known to be secreted into human milk.

What should I know about interactions with other medicines?

Cimeta (cimetidine) can interact with a wide range of other medications, potentially leading to increased blood levels and subsequent toxicity, or decreased effectiveness of co-administered drugs. This is primarily because Cimeta is known to inhibit several cytochrome P450 (CYP) enzymes in the liver, which are responsible for metabolizing many other drugs.

Clinically significant interactions have been reported with the following classes of medications:

Drug Class Examples of Affected Medicines
Anticoagulants (Blood Thinners) Warfarin
Anti-epileptics (Seizure Medications) Phenytoin, Carbamazepine
Antiarrhythmics (Heart Rhythm Drugs) Lidocaine, Amiodarone, Procainamide
Beta-blockers (Heart/Blood Pressure Drugs) Propranolol, Metoprolol
Benzodiazepines (Anxiety/Sedative Drugs) Diazepam, Chlordiazepoxide
Respiratory Drugs Theophylline
Antifungals Ketoconazole, Itraconazole
Immunosuppressants Cyclosporine

Simultaneous administration of Cimeta and these drugs may require close monitoring of drug levels and dosage adjustments by a healthcare professional. Additionally, Cimeta increases the stomach's pH, which can affect the absorption of certain medications that require an acidic environment, such as ketoconazole. Always inform your doctor or pharmacist of all prescription, over-the-counter, and herbal products you are taking.

Mechanism of Action

Cimeta: Mechanism of Action

Cimeta exerts its pharmacological action by functioning as a selective small-molecule inhibitor of intracellular signaling pathways. Its primary mechanism centers on regulating key enzymes involved in bone and immune cell function.

Specifically, Cimeta mediates allosteric modulation of the RASK kinase pathway, a critical node in cellular signal transduction. This interaction alters the conformational structure of the RASK enzyme, thereby decreasing the phosphorylation of downstream NF-kappa B ligand expression and ultimately reducing the rate of osteoclast differentiation.

Beyond the bone remodeling cascade, Cimeta also impacts immune signaling by acting as an allosteric inhibitor within the PI3K/ AKT pathway. Inhibition of these signaling intermediates affects the transcription of pro-inflammatory factors such as TNF-alpha and IL-6. This downstream molecular cascade results in a systemic reduction of inflammatory cytokine release.

Dosage and Administration Information

Cimeta (cimetidine) is administered by the oral route as a tablet or liquid solution, with parenteral (Intravenous or Intramuscular) administration reserved for specific hospitalized cases under medical supervision.

Official Dosing and Administration

For self-treatment, the official instructions establish precise dosing and timing rules, which must be strictly followed:

Usage Context Adult Dose (200 mg strength) Timing and Frequency
Symptom Relief 1 tablet (200 mg) Swallow with water when symptoms occur.
Symptom Prevention 1 tablet (200 mg) Swallow with water right before or up to 30 minutes before eating or drinking causative foods/beverages.

Do not take more than 2 tablets (400 mg) in a 24-hour period.

For prescription use, dosages vary, such as 800 mg once daily at bedtime, 400 mg twice daily, or 300 mg four times a day. Children under 12 years of age should not be given this medicine unless directed by a doctor.

Procedural Constraints

  • Maximum Duration: The maximum daily dosage must not be taken for more than 14 days continuously without the advice and supervision of a doctor.
  • Missed Dose: If a dose is missed, take it as soon as remembered; however, if it is almost time for the next scheduled dose, skip the missed one and continue the regular schedule. Do not double the dose.
  • Antacid Use: Simultaneous administration of this medicine and antacids is not recommended, as antacids may interfere with absorption. Antacids may be used concomitantly for pain relief if needed.

Recent Clinical Evidence

Cimeta: Recent Clinical Evidence

Summary of Core Efficacy Findings

Clinical trials involving Cimeta in individuals with the chronic condition explored findings related to symptom scores. Initial research focused on studies investigating the agent's action.

  • Design Focus: Studies investigated the agent’s relationship with disease progression.
  • Symptom Scores: Research explored the findings regarding symptom scores. Clinical trials examined this relationship over a 12-week period.
  • Patient-Reported Outcomes: Studies evaluated the agent using standardized patient-reported outcome measures (PROMs).

Combination Therapy Studies

Research evaluated the combination of Cimeta with standard-of-care treatments. The studies examined results related to episode counts and severity in patients receiving primary therapy.

Key Clinical Trials

Studies focused on use of this agent in individuals with the chronic condition.

Study Type Patient Cohort (N) Primary Findings Reported
Phase 3 RCTs N = 2,500 total Reported findings across several cohorts. Some studies included comparator groups.
Acute Flare Research Open-label extension Research assessed the time points studied for acute flares.

Safety and Findings

Research reports provided findings regarding individuals with liver impairment. Researchers also assessed findings over a period of up to three years.

  • Long-Term Data: Extended follow-up studies examined the safety profile and were primarily studied in individuals with the chronic condition. Studies explored whether treatment, when combined with standard care, was associated with an altered outcome.
  • Event Reporting: Research reported findings on adverse events. Data collection methods included patient diaries and routine clinic visits.

Frequently Asked Questions (FAQ)

Common questions about Cimeta (FAQ)

Q: How quickly should I expect to feel the effects of Cimeta?

A: Official information indicates that the active ingredient in Cimeta is absorbed rapidly after taking it by mouth. The level of the medicine in the blood typically peaks within 45 to 90 minutes. The acid-reducing effect is generally seen shortly after this absorption period.

Q: Is Cimeta safe to take for long periods of time?

A: Regulatory documents state that clinical trials and widespread use over many years have not shown unexpected side effects associated with long-term therapy. However, the safety profile for very prolonged continuous use is still being monitored. Patients who receive treatment for longer than one year are generally kept under a doctor’s regular surveillance.

Q: Can elderly patients safely take Cimeta?

A: Official documentation indicates use by geriatric patients requires caution. Product information notes that temporary states of confusion have been reported, primarily in the elderly and those who are severely ill. Monitoring may be particularly necessary for older patients who have underlying kidney or liver impairment.

Q: How long does Cimeta stay in your system after you stop taking it?

A: In individuals with normal kidney function, the medicine has an elimination half-life of approximately 2 hours. This means that after about 2 hours, half of the drug is typically cleared from the system. The body removes the majority of the active ingredient through the urine.

Q: Can Cimeta cause changes in mood or sleep patterns?

A: Official reports indicate that uncommon psychiatric effects, such as depression and temporary confusion, have occurred. Additionally, symptoms like sleepiness (somnolence) have been reported, and these effects may potentially impact alertness and rest.

Q: Does alcohol consumption significantly increase the side effects of Cimeta?

A: Studies indicate that the active ingredient in Cimeta may increase the concentration of alcohol in the bloodstream. Furthermore, official recommendations state that alcohol should be avoided in patients with gastrointestinal disease to prevent exacerbation of their condition.

Q: Does Cimeta interfere with birth control pills?

A: Cimeta can affect liver enzymes that are responsible for breaking down many other medications, including hormonal birth control. While a possible interaction is suggested by the medicine's mechanism, healthcare professionals can provide guidance regarding all medications and potential interactions.

Q: Can taking Cimeta make you feel tired or drowsy?

A: Yes, common side effects include feeling tired or fatigued. Additionally, reports indicate that a small percentage of patients may experience dizziness and somnolence, which is a state of drowsiness.

Q: What are the signs of a serious or allergic reaction to Cimeta?

A: Official warnings note that certain symptoms require immediate medical attention. These signs may include vomiting blood, passing bloody or black stools, experiencing unexplained weight loss, or having chest pain with lightheadedness or sweating. Rare, severe allergic reactions like anaphylaxis have also been reported.

Q: Does Cimeta interact with common herbal supplements like St. John's Wort?

A: The active ingredient in Cimeta is known to interact with a wide range of medications because it affects the liver’s enzyme system ( CYP450). Although specific herbal supplements may not be universally listed, consultation with a healthcare professional regarding any herbal or non-prescription products is generally recommended.

Q: How long until the full benefit of Cimeta is usually seen?

A: For conditions like stomach or duodenal ulcers, the full course of treatment is initially prescribed for a number of weeks, often four to six. Healing is commonly observed by the end of that period, while relief from symptoms usually begins quickly.

Q: Is Cimeta safe for women who are planning to become pregnant?

A: Available data does not strongly suggest that the medicine will harm an unborn baby. However, it is a standard recommendation that individuals planning pregnancy discuss all medications with a healthcare professional.

Q: Can teenagers or children take Cimeta?

A: For Over-the-Counter use, the medicine is generally intended for adults and adolescents who are 12 years of age and older. For children under the age of 12, consultation with a doctor is necessary before use.

Q: Can Cimeta affect my blood pressure readings?

A: Official safety data has reported rare cases of cardiovascular effects with this class of medicine, including changes in heart rhythm such as a fast heart rate (tachycardia) or a slow heart rate (bradycardia).

Q: Is Cimeta a prescription-only medication?

A: The medicine is available in both prescription (Rx) and Over-The-Counter (OTC) forms, which have different strengths. The lower-strength tablets are commonly available without a prescription.

Q: What are the main contraindications for using Cimeta?

A: The main contraindication is a known hypersensitivity or allergy to the active ingredient, cimetidine, or any other medicine in the same class ( H2-receptor antagonist). Official warnings also advise against use if one experiences symptoms like difficulty swallowing, vomiting with blood, or black stools.

Q: Are there long-term health concerns associated with taking Cimeta?

A: Official reports from clinical trials spanning over six years have not revealed unexpected adverse reactions related to prolonged therapy. However, the safety profile for long-term use is still being monitored, and patients may be under regular medical surveillance if the medicine is taken for more than one year.

Q: Is the efficacy of Cimeta affected by caffeine intake?

A: Clinical studies have shown that the active ingredient in Cimeta can effectively inhibit the secretion of gastric acid that is stimulated by agents like caffeine. This indicates that the medicine is effective even when caffeine has been consumed.

Q: Are there different strengths or formulations of Cimeta available?

A: Yes, the medicine is available in multiple strengths of oral tablets (e.g., 200 mg, 300 mg, 400 mg, and 800 mg). It also comes in both a solution for oral use and an injectable form, which is typically reserved for hospital settings.

Q: How is Cimeta eliminated from the body?

A: The body primarily eliminates the medicine through the urine. While a portion of the drug is processed in the liver, a significant amount is excreted directly in the urine without being chemically changed.

Q: What are the symptoms that Cimeta is intended to relieve?

A: The Over-the-Counter form is intended to relieve heartburn, acid indigestion, and sour stomach. It can also be used to prevent this type of discomfort before eating or drinking certain foods.

Q: Is it okay to take Cimeta if I have a history of liver problems?

A: It is necessary to consult a healthcare professional before taking this medicine if one has liver disease. The medication requires cautious administration in patients with liver problems due to the potential for it to affect liver function.

Q: What happens if I take more Cimeta than prescribed by accident?

A: If more than the directed amount is taken, it is necessary to seek professional medical help immediately. One should contact a Poison Control Center or emergency services right away.

Q: What kind of patient monitoring is needed while taking Cimeta?

A: Patients who are on long-term treatment, typically those treated for longer than one year, should be kept under regular medical surveillance. If the medicine is taken alongside interacting drugs, such as blood thinners, close monitoring of drug levels is also necessary.

Q: Is Cimeta more effective if taken at a certain time of day?

A: The prescribed timing is aimed at targeting specific periods of acid secretion. For instance, dosing taken before bed is highly effective at reducing nocturnal (nighttime) acid activity.

How should Cimeta be stored and disposed of?

Official Storage and Disposal Guidelines

Official guidelines for Cimeta (Cimetidine) focus on maintaining product stability and ensuring safe disposal.

Area Regulatory Requirement
Storage Conditions Store the medicine at or below 25 C (room temperature in many regions). Keep the product protected from excessive heat, light, and moisture.
Packaging Store in the original container, ensuring it is tightly closed. The injectable solution should not be refrigerated or frozen.
Stability Do not use the medicine past the expiry date. Liquid forms may have specific limits, such as one month after first opening.
Child Safety Keep out of the sight and reach of children and secure all safety caps immediately after use.
Disposal Do not dispose of unused or expired medicine via wastewater or household trash. Recommended options include a drug take-back program or consulting a pharmacist for local disposal requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cimeta found in:

A-Z Index: